Corrigendum to "Cetuximab in locally advanced head and neck squamous cell carcinoma: Biological mechanisms involved in efficacy, toxicity and resistance" [Crit. Rev. Oncol./Hematol. 164 (2021) 1-11/103424]
1 Immunopathology and Cancer Biomarkers Unit, Department of Translational Research, CRO Aviano National Cancer Institute, Aviano, PN, Italy. Electronic address: emuraro@cro.it.
2 Department of Radiation Oncology, CRO Aviano National Cancer Institute, Aviano, PN, Italy.
3 Unit of Otolaryngology, General Hospital "S. Maria degli Angeli", Pordenone, Italy.
4 Immunopathology and Cancer Biomarkers Unit, Department of Translational Research, CRO Aviano National Cancer Institute, Aviano, PN, Italy.
5 Department of Medical Oncology, CRO Aviano National Cancer Institute, Aviano, PN, Italy.